Linshom Medical wins $100K MIPS grant for respiratory monitoring trial

Linshom Medical received a $100,000 Phase 2 grant from Maryland Industrial Partnerships to support an interventional clinical trial with the University of Maryland School of Medicine. The study will test whether the company’s respiratory monitoring device can trigger earlier intervention in the post-anesthesia care unit and reduce serious respiratory events.

Why it matters: - The trial is designed to test whether earlier warnings can help clinicians intervene before patients deteriorate in the post-anesthesia care unit. - Linshom Medical is positioning its device as a tool to reduce rapid response activations, rescue events, intensive care unit transfers and deaths tied to respiratory compromise.

What happened: - Linshom Medical received a $100,000 Phase 2 grant from Maryland Industrial Partnerships on August 6, 2026. - The grant will support an interventional clinical trial led by faculty from the University of Maryland School of Medicine. - The study will evaluate Linshom Medical’s respiratory monitoring device in the post-anesthesia care unit.

The details: - Donald R. Herdt, MD, MBA, principal investigator and assistant professor of anesthesiology at UMSOM, said the trial follows a Phase 1 clinical study completed last year. - Herdt said the Phase 1 study showed the device could detect respiratory depression episodes 25 minutes before current standard of care. - The Phase 2 trial will measure the effect of early intervention after those early warnings. - Richard Hughen, chief executive officer of Linshom Medical, said current monitoring tools warn after a patient is already in respiratory trouble. - Hughen said predictive notice of respiratory decline could help providers avoid costly escalation events. - MIPS offers matching grants for collaborative research projects between Maryland-based companies and University System of Maryland institutions. - MIPS awards the grants competitively based on joint proposals from companies and university researchers.

Between the lines: - The award gives Linshom Medical outside validation and funding to move from detection performance to clinical impact. - The key question now is not whether the device can spot risk earlier, but whether that earlier signal changes outcomes in practice.

What's next: - The University of Maryland School of Medicine team will launch the interventional trial. - Researchers will measure whether early intervention after device alerts improves patient care in the PACU. - Linshom Medical says its device delivers continuous real-time respiratory data, including respiratory rate, relative tidal volume and seconds since last breath.

The bottom line: - Linshom Medical now has funding to test whether earlier respiratory warnings can translate into fewer complications at the bedside. - The trial could determine whether the device’s predictive approach delivers clinical benefit beyond standard monitoring.